A Phase 3 Study to Evaluate the Safety and Tolerability of L606 in Subjects With PAH or PH-ILD (NCT04691154) | Clinical Trial Compass
Active — Not RecruitingPhase 3
A Phase 3 Study to Evaluate the Safety and Tolerability of L606 in Subjects With PAH or PH-ILD
United States28 participantsStarted 2021-08-01
Plain-language summary
This Phase 3, 2-part, open-label, multicenter study aims to demonstrate the safety and tolerability of L606 in patients with PAH or PH-ILD. The study will determine the short-term and long-term safety and tolerability of L606 in this patient population.
Who can participate
Age range18 Years – 80 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
✓. Males and females ≥18 and ≤80 years of age.
✓. Diagnosed with
✓. PAH belonging to at least 1 of the following subgroups of Group 1 pulmonary hypertension (PH) per European Society of Cardiology/European Respiratory Society Guidelines for the diagnosis and treatment of PH at least 1 year prior to screening. or
✓. PH-ILD Group 3 European Society of Cardiology/European Respiratory Society Guidelines for the diagnosis and treatment of PH. Subjects with Group 3 PH that is not related to underlying ILD are not eligible.
✓. Subjects with PAH: Documentation of having PAH as confirmed by RHC meeting the following criteria:
✓. NYHA functional class II, III, or IV at the screening visit.
✓. Can complete a screening 6MWD of ≥150 meters
✓. For subjects with PAH: \>65% of predicted and FEV1/FVC ratio \>65% at screening. For subjects with PH-ILD: \>40% of predicted and FEV1/FVC ratio \>70% at screening.
Exclusion criteria
✕. LVEF of ≤45% on a historical echocardiogram.
✕. History of sleep apnea, or left-sided heart disease (including but not limited to aortic or mitral valve disease, pericardial constriction, restrictive or congestive cardiomyopathy, or coronary artery disease) per investigator's discretion.
✕. Experienced an acute exacerbation of disease or hospitalization for any reason within 30 days of signing the ICF or prior to baseline.
What they're measuring
1
Safety/Tolerability assessed by incidence of treatment-emergent AEs/SAEs
Timeframe: 2 weeks
2
Safety/Tolerability assessed by incidence of treatment-emergent AEs/SAEs
Timeframe: 12 weeks
3
Safety/Tolerability assessed by incidence of treatment-emergent AEs/SAEs (long-term)
✕. Musculoskeletal disorder (eg, arthritis affecting the lower limbs, recent hip or knee joint replacement) or any disease that would likely be the primary limit to ambulation or subject is connected to a machine that is not portable enough to allow for a 6MWT.